Compare · NVO vs SMMT
NVO vs SMMT
Side-by-side comparison of Novo Nordisk A/S (NVO) and Summit Therapeutics Inc. (SMMT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SMMT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $218.21B, about 18.4x SMMT ($11.88B).
- Over the past year, NVO is down 28.5% and SMMT is down 39.8% - NVO leads by 11.3 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 1 for SMMT).
- NVO has more recent analyst coverage (25 ratings vs 22 for SMMT).
- Company
- Novo Nordisk A/S
- Summit Therapeutics Inc.
- Price
- $49.28-0.40%
- $15.29+0.26%
- Market cap
- $218.21B
- $11.88B
- 1M return
- +15.17%
- +17.34%
- 1Y return
- -28.54%
- -39.80%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- News (4w)
- 5
- 1
- Recent ratings
- 25
- 22
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest SMMT
- The New War on Cancer: Four Public Companies Helping Lead a Medical Revolution
- Summit Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Co-Chief Executive Officer Zanganeh Mahkam bought $49,987,200 worth of shares (3,810,000 units at $13.12) (SEC Form 4)
- Co-Chief Executive Officer Duggan Robert W bought $49,987,200 worth of shares (3,810,000 units at $13.12), increasing direct ownership by 0.67% to 573,883,879 units (SEC Form 4)
- Summit Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Summit Therapeutics Announces Proposed Public Offering of Common Stock
- SEC Form S-3ASR filed by Summit Therapeutics Inc.
- Co-Chief Executive Officer Duggan Robert W bought $1,460,000 worth of shares (100,000 units at $14.60) (SEC Form 4)
- Co-Chief Executive Officer Zanganeh Mahkam bought $1,460,000 worth of shares (100,000 units at $14.60) (SEC Form 4)
- COO and CFO Soni Manmeet Singh bought $722,250 worth of shares (50,000 units at $14.45), increasing direct ownership by 2% to 3,123,603 units (SEC Form 4)